AASLD
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

HEPATOLOGY COMMUNICATIONS

Open Access

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES



OPEN ACCESS

HEPATOLOGY COMMUNICATIONS

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

AASLD National Headquarters: 1001 North Fairfax Street, 4th floor, Alexandria, VA 22314. **Phone:** 703-299-9766; **Fax:** 703-299-9622; **E-mail:** AASLD@AASLD.org. Interim Chief Executive Officer, Julie Deal
Editorial Office: 1001 North Fairfax Street, Suite 400, Alexandria, VA 22314. **Phone:** 703-299-9766; **Fax:** 703-299-9676; **E-mail:** HEPCOMM@AASLD.ORG

IN THIS ISSUE OF

HEPATOLOGY COMMUNICATIONS

Volume 3 • Number 6 June 2019

Editorial



Cover Figure: Old dogmas versus new insights on liver macrophages. Liver macrophages have long been regarded as a homogeneous population and designated as F4/80+ KCs. Innovative new techniques, such as cell tracking, multi-omics phenotyping, and single-cell RNA sequencing, unraveled a previously unrecognized heterogeneity in liver macrophage origins and functions. The simplistic dichotomic view of M1- versus M2-polarized macrophages also appears outdated as macrophages of virtually all intermediate phenotypes have been described depending on the pathology or activating signals they are exposed to. Considering the multifaceted roles of liver macrophages in promoting or preventing tissue damage and repair, immunomodulating (e.g., gene expression modulation, chemokine receptor antagonism, à la carte activating signals) rather than immunodepleting approaches need to be considered.

Review

Brief Report

Original Articles

Correspondence